BioNexus Gene Lab Total Liabilities 2019-2025 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab total liabilities from 2019 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

BioNexus Gene Lab Total Liabilities 2019-2025 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

BioNexus Gene Lab total liabilities from 2019 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$133.5B
Elevance Health (ELV)	$96.1B
CVS Health (CVS)	$84.8B
Cencora (COR)	$55.6B
DiDi Global (DIDIY)	$20.3B
Natera (NTRA)	$20B
BioMerieux (BMXMF)	$15.6B
Solventum (SOLV)	$11.5B
ICON (ICLR)	$11.3B
EUROFINS SCIENT (ERFSF)	$11.1B
Revvity (RVTY)	$11B
CochLear (CHEOY)	$10.9B
Avantor (AVTR)	$10.3B
Doximity (DOCS)	$9.9B
Viatris (VTRS)	$9B
Medpace Holdings (MEDP)	$9B
Sonic Healthcare (SKHHY)	$7.7B
HealthEquity (HQY)	$7.3B
Charles River Laboratories (CRL)	$5.2B
Amplifon S.p.A (AMFPF)	$4.3B
Bausch + Lomb (BLCO)	$4.3B
Alignment Healthcare (ALHC)	$3.5B
Sotera Health (SHC)	$3B
BrightSpring Health Services (BTSG)	$2.9B
Organon (OGN)	$2.9B
Surgery Partners (SGRY)	$2.7B
GeneDx Holdings (WGS)	$2.7B
Concentras Parent (CON)	$2.6B
Progyny (PGNY)	$1.8B
Ardent Health Partners (ARDT)	$1.8B